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BACKGROUND The purpose of this study was to compare directly the
aortic annulus measurement by multi detector computed tomography
(MDCT) between a Japanese multi-center registry and a European
single-center experience undergoing transcatheter aortic valve im-
plantation (TAVI).
METHODS Between October 2013 and July 2014, 90 patients who are
undergoing TAVI were prospectively included in the OCEAN-TAVI
registry from 3 Japanese centers (Keio university hospital, Toyohashi
heart center, and Teikyo university hospital). Between March 20 09
and December 201 2, 181 consecutive patients undergoing TAVI who
had pre-procedural MDCT at Institut Cardiovasculaire Paris Sud were
prospectively included in the European cohort. We compared MDCT
aortic annulus measurement of these 2 cohorts.
RESULTS Patients were of similar age (85.0 [Interquartile Range (IQR)
82.5-87.5] vs 84.0
[IQR 80.5-87.5] years, p¼0.83), and body surface area was smaller in
the Japanese registry (1.400.15 vs 1.760.00319, p<0.01). All annulus
dimensions including short annulus diameter (19.42.0 vs 22.62.3,
p<0.01), large annulus diameter (24.71.9 vs 27.62.5, p<0.01),
calculated average annulus diameter by area (CAAD, 22.41.6 vs
25.62.2, p<0.01), left coronary ostium height (13.6 [IQR 12.0-15.0]
vs15.1 [IQR 13.5-17.2] , p<0.01) and right coronary ostium height (15.9
[IQR 14.5-17.5] vs 17.7 [IQR 16.0-19.7] , p<0.01) were smaller in a
Japanese registry. With hypothetical prosthesis sizing based on CAAD
(20mm Edwards Sapien XT for <20 mm; 23mm: 20 to 22mm; 26mm: 22
to 25 mm; 29mm: >25 mm), the use of 20mm, 23mm, 26mm, and
29mm Edwards valve compared with a Japanese registry and an Eu-
ropean cohort were 2.2% vs 0%, 51.1% vs 12.7%, 44.4% vs 43.1%, and
2.2% vs 44.2% (p<0.01), respectively.
CONCLUSION Japanese patients had smaller annulus dimensions by
MDCT compared with European patients. Prosthesis sizing by CAAD
showed smaller size of prosthesis would be required among Asian
patients undergoing TAVI.
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BACKGROUND MitraClip has been increasingly performed in Asian
countries since 2011. Our study is to evaluate the effectiveness of
improvement of heart failure symptoms and functional status in heart
failure patients with percutaneous method of reduction of mitral
incompetence (MI) with the MitraClip system.
METHODS Patients were selected for the MitraClip procedure based
on the consensus of the Heart Team in our center. Between February
2012 and December 2013, 24 patients considered high risk as surgical
candidates undergone percutaneous therapy for severe MI using the
MitraClip. All the patients underwent clinical and echocardiographic
evaluation at baseline, and at 6-month follow-up. Mortality data,
including cause of death, were collected.
RESULTS The mean age was 67 years (53–86), 58.3% (n ¼ 14) was male
with a mean logistic EuroSCORE of 21%. At baseline, 90% of patients
were in New York Heart Association (NYHA) functional class III or IV
and 46% of patients had a left ventricular ejection fraction
(LVEF) 50%. 45.8% (n¼11) patients presented with functional mitral
regurgitation (FMR) and 54.2% (n¼13) patients presented with
degenerative mitral regurgitation (DMR). Procedural success was
achieved in 96% of patients. Severity of MR was reduced in allsuccessfully treated patients, 18 (75%) were discharged with MR 2þ.
There was improvement in the severity of MI at 6 months, compared
with baseline (p < 0.0001), Thirty-day mortality was 6%. At 6 months,
approximately 90% of patients had New York Heart Association
functional class II or class I (p <0.0001).
CONCLUSION Results of the study demonstrate that mitral incom-
petence reduction with MitraClip treatment is effective, low risk, and
leads to signiﬁcant improvement in NYHA functional class in
approximately 90% of patients with heart failure.TCTAP A-118
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BACKGROUND A novel and innovative transfemoral aortic valve im-
plantation (TF-AVI) system was used to treat 89 patients with severe
aortic stenosis in a CE mark trial. This single-arm registry was per-
formed at 6 clinical sites in Brazil, Germany and Japan. The ﬁrst pa-
tient was implanted in January 2012 and the last study implant
procedure took place in early October 2013.
METHODS These 89 high-risk patients afﬂicted with severe aortic
stenosis were treated in single-arm trials conducted at 6 centers
in Brazil, Germany and Japan. Treated patients have a mean age of
83.7  4.4 years, an STS Score of 7.5  8.2%, and a logistic
EuroSCORE of 26.6 7.7%. Baseline mean aortic gradient was 43.6
 17.1 mmHg and mean AVA was 0.7  0.2 cm2. Nearly all patients
presented in NYHA ClassIII/IV at screening (n¼84) and 65.2% were
female. All patients provided EC-approved written informed
consent.
RESULTS Procedure success rate was 94.4% (n¼84) with 3 valve-in-
valve procedures and 2 failed implantations due to one instance of
annular rupture and one case of bioprosthesis leaﬂet tear. Both failed
procedures occurred during post-dilatation. The implant procedures
were performed using small, medium and large valves covering an
annular range of 21 mm to 27 mm. At 30 days there were 3 deaths, 2
strokes and no MI reported. Only 8 new pacemaker implantations
were required for a rate of 9.0%. Freedom from VARC II combined
safety at 30 days was 84.3% (n¼75). Echocardiography at 30 days
revealed only 4 patients (4.9%) with moderate (grade 2) paravalvular
leak – there were no patients with a paravalvular leak above grade 2.
The mean gradient was reduced to 8.0  2.9 mmHg and the aortic
valve area was 1.8 0.3 cm2. At 12 months, all-cause mortality was
22.5% (n¼20) with 3 additional strokes and one myocardial infarction
reported.
CONCLUSION Outcomes from treatment with this new 2ndGeneration
TF-AVI system conﬁrm its feasibility of use and safety out to one year.
In September 2014 this device received CE mark approval, and further
postmarket data may be expected in the near future.
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BACKGROUND Data on transcatheter aortic valve implantation
(TAVI)in bicuspid aortic valve (BAV) is rare and inconsistent,
particularly concerning incidence and outcome. In part this might be
attributed to an inadequate recognition of this condition and/or a
relatively low sensitivity of echocardiography. However, multislice
computed tomography (MSCT) is thought to have a better diagnostic
accuracy.
The aim of this retrospective analysis was to review MSCTs for
detection and classiﬁcation of BAVs and verify the impact on proce-
dural outcome.
